Gamgee launches startup for AI-designed dog cancer vaccines
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Gamgee launched to offer personalized mRNA cancer vaccines for dogs, with ambitions extending to personalized treatments for other diseases and species including humans
- Paul Conyngham founded Gamgee around the story of Rosie, his Staffordshire bull terrier-Shar Pei mix, whose tumors he claims shrank after he used ChatGPT and computational genomics to design a personalized mRNA vaccine
- The Verge's earlier reporting questioned the science, noting researchers said the claims gave AI too much credit while minimizing the role of humans, and that the protocol — which paired the vaccine with another therapy — made it impossible to attribute Rosie's improvement to the vaccine alone
- Gamgee is backed by Y Combinator and is recruiting for its first clinical trials in Australia, with a waitlist open globally; Conyngham emphasizes on the website that he is 'not a biologist'
- Gamgee claims roughly 75 percent tumor reduction in its 'first documented case' and says it can deliver a finished vaccine to veterinarians in around four weeks, though it cautions the timeline is based on a single case
- Gamgee says it is collaborating with the University of Queensland and institutes at the University of New South Wales, and is encouraging potential funders and study partners to reach out
Why it matters: Gamgee is commercializing a treatment built on a single case whose causal link to the AI-designed vaccine was already disputed by researchers, yet it has secured Y Combinator backing and is launching clinical trials in Australia — meaning real dogs (and potentially humans) could soon receive a therapy whose central proof point is the same anecdote now powering its marketing.
Ask SkimNews
